Medication info

Canderova Tablet 20/32 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]
Approval status
Active

MFDS item code 202008713 · Approved 2020.12.11

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. Heart failure: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbeta-lipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medication is used in patients who require the combined administration of the two components, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used for patients with essential hypertension and heart failure, particularly effective in those with impaired left ventricular systolic function who have not responded adequately to ACE inhibitors or have poor tolerance. Rosuvastatin is used in patients with hypercholesterolemia and dyslipidemia in conjunction with dietary and exercise therapy or as an adjunct, reducing blood cholesterol levels and delaying the progression of atherosclerosis. It also helps to reduce the risk of stroke, myocardial infarction, and arterial revascularization in patients at high risk of cardiovascular disease. Thus, the combined administration of the two drugs is used to effectively manage hypertension and dyslipidemia, reducing the risk of cardiovascular disease.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. Heart failure: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication may cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. This medication is contraindicated in patients with a known allergy to it, those with severe liver function impairment, and those with certain genetic lactase metabolism disorders. Special caution should be taken in elderly patients, those with impaired kidney function, and those with hyperkalemia, and regular blood tests and liver function tests should be performed under a doctor's advice. If symptoms such as myalgia or muscle weakness occur, immediate consultation with a physician is necessary, and in severe cases, it may be required to discontinue the medication. Interactions may occur if taken with other antihypertensive medications or certain lipid-lowering drugs; therefore, it is essential to inform the doctor or pharmacist of any other medications being taken. Caution is warranted as dizziness or fatigue may occur when driving or operating machinery. Women who could become pregnant should use appropriate contraception before taking this medication, and breastfeeding women are advised to avoid it. In cases of overdose, seek medical attention immediately, and since there is no specific antidote, treatment will be symptomatic. The safety and efficacy of this medication in children have not been established, thus it is not recommended. Keep the medication out of reach of children and do not transfer it from its original container to another.

Side effects

  • Headache
  • nasopharyngitis
  • localized infection
  • fatigue
  • generalized pruritus
  • dermatitis
  • itching
  • joint stiffness
  • limb pain
  • photophobia
Show 84 more
  • dyspepsia
  • increased blood sugar
  • decreased serum sodium
  • hand fracture
  • hypoglycemia
  • nephrolithiasis
  • cough
  • dizziness
  • orthostatic dizziness
  • meibomian cyst
  • periodontitis
  • inflammation
  • musculoskeletal pain
  • neck pain
  • cataract
  • nausea
  • chest discomfort
  • foreign body sensation
  • rash
  • urticaria
  • angioedema
  • weakness
  • fever
  • paresthesia
  • dyspepsia
  • gastroenteritis
  • tachycardia
  • palpitation
  • hyperglycemia
  • hypertriglyceridemia
  • hyperuricemia
  • myalgia
  • epistaxis
  • anxiety
  • depression
  • somnolence
  • dyspnea
  • hematuria
  • thrombocytopenia
  • jaundice
  • hepatitis
  • increased creatine kinase
  • myopathy
  • rhabdomyolysis
  • lupus-like syndrome
  • muscle rupture
  • immune-mediated necrotizing myopathy
  • amnesia
  • peripheral neuropathy
  • diarrhea
  • Stevens-Johnson syndrome
  • erectile dysfunction
  • sleep disorder
  • decreased libido
  • forgetfulness
  • loss of appetite
  • increased appetite
  • tinnitus
  • taste disturbance
  • angioedema
  • increased blood pressure
  • orthostatic hypotension
  • cerebral infarction
  • inflammatory spondylitis
  • musculoskeletal discomfort
  • pneumonia
  • femur fracture
  • contusion
  • unstable angina
  • idiopathic pulmonary fibrosis
  • moist cough
  • exacerbation of hypertension
  • unstable blood pressure
  • dizziness
  • orthostatic dizziness
  • adrenal insufficiency
  • intestinal vasculitis
  • thirst
  • weight gain
  • facial edema
  • syncope
  • generalized pain
  • muscle cramps
  • gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.